Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 16:01 ET
|
Retrophin, Inc.
Top-line results from pivotal Phase 3 FORT Study in PKAN expected in 3Q 2019 Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS...
Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
February 13, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection Trials Aim to Show...
Retrophin Completes Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN
December 20, 2018 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced completion of patient enrollment in the pivotal Phase 3 FORT Study, which is evaluating the safety and...
FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease
December 20, 2018 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today...
Retrophin Reports Third Quarter 2018 Financial Results
November 01, 2018 16:01 ET
|
Retrophin, Inc.
Pivotal programs enrolling towards first data readout in 2019 Phase 2 study of CNSA-001 in PKU underway; top-line results expected in first half 2019 Completed offering of $276 million...
VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
October 16, 2018 08:00 ET
|
VBI Vaccines, Inc.
Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE...
Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease
October 04, 2018 09:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
ERYTECH annonce le recrutement des premiers patients dans son étude clinique de Phase 3 avec eryaspase pour le traitement en seconde ligne du cancer du pancréas
September 20, 2018 01:30 ET
|
Erytech Pharma S.A.
LYON, France et CAMBRIDGE, Mass., 20 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), société biopharmaceutique de stade clinique qui développe des thérapies...
ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer
September 20, 2018 01:30 ET
|
Erytech Pharma S.A.
LYON, France and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies...
uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress
August 08, 2018 07:00 ET
|
uniQure Inc.
~ Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061 ~ First Patient Successfully Screened into Phase IIb Dose-Confirmation Trial of AMT-061 ~ Robert Gut, M.D., Ph.D.,...